Evaluation of Drug-Drug Interactions Between Hepatitis C Antiviral Agents Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and HIV-1 Protease Inhibitors

Clinical Infectious Diseases

Volumn 62, Issue 8, 2016, Pages 972-979

  Khatri, Amit ^a,b   Dutta, Sandeep ^a   Wang, Haoyu ^a   Podsadecki, Thomas ^a   Trinh, Roger ^a   Awni, Walid ^a   Menon, Rajeev ^a  

^a ABBVIE INC   (United States)

^b Clinical Pharmacology and Pharmacometrics   (United States)

Author keywords

direct acting antiviral HCV drugs; hepatitis C; HIV; HIV protease inhibitors; pharmacokinetics

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; BILIRUBIN; DARUNAVIR; DARUNAVIR PLUS RITONAVIR; DASABUVIR; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; OMBITASVIR; PARITAPREVIR; PARITAPREVIR PLUS RITONAVIR; RITONAVIR; UNCLASSIFIED DRUG; ABT-267; ABT-333; ABT-450; ANILIDE; CARBAMIC ACID DERIVATIVE; MACROCYCLIC COMPOUND; SULFONAMIDE; URACIL;

ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; ATRIOVENTRICULAR BLOCK; BLOOD SAMPLING; CONTACT DERMATITIS; DIARRHEA; DIZZINESS; DRUG INTERACTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; EVENING DOSAGE; EYE JAUNDICE; FATIGUE; FEMALE; FIRST DEGREE ATRIOVENTRICULAR BLOCK; HEADACHE; HUMAN; HUMAN EXPERIMENT; MACULOPAPULAR RASH; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; NAUSEA; PHARMACOKINETIC PARAMETERS; PRIORITY JOURNAL; RHINOPHARYNGITIS; SIDE EFFECT; UNPLEASANT DREAM; ADOLESCENT; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COINFECTION; COMBINATION DRUG THERAPY; COMPLICATION; DRUG ADMINISTRATION; DRUG EFFECTS; HEPACIVIRUS; HEPATITIS C; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; MIDDLE AGED; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; ANILIDES; ANTIVIRAL AGENTS; CARBAMATES; COINFECTION; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HEALTHY VOLUNTEERS; HEPACIVIRUS; HEPATITIS C; HEPATITIS C, CHRONIC; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MACROCYCLIC COMPOUNDS; MALE; MIDDLE AGED; RITONAVIR; SULFONAMIDES; URACIL; YOUNG ADULT;

EID: 84964825681     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ1213     Document Type: Article

References (30)

1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available at: http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed 14 October 2014.
2. Gunthard HF, Aberg JA, Eron JJ, et al. Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel. JAMA 2014; 312:410-25.
3. European AIDS Clinical Society. European AIDS clinical society guidelines, version 7.1. Brussels, Belgium: European AIDS Clinical Society, 2014.
4. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Geneva, Switzerland: World Health Organization, 2013.
5. Rathbun RC, Liedtke MD. Antiretroviral drug interactions: overview of interactions involving new and investigational agents and the role of therapeutic drug monitoring for management. Pharmaceutics 2011; 3:745-81.
6. Andreone P, Colombo MG, Enejosa JV, et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology 2014; 147:359-65.e1.
7. Ferenci P, Bernstein D, Lalezari J, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 2014; 370:1983-92.
8. Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014; 370:1973-82.
9. Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370:1594-603.
10. Sulkowski MS, Eron JJ, Wyles D, et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. JAMA 2015; 313:1223-31.
11. Khatri A, Wang H, Wang T, et al. Drug-drug interactions of the direct acting antiviral regimen of ABT-450/r, ombitasvir and dasabuvir with HIV protease inhibitors. Presented at: 54th Interscience Conference on Antimicrobial Agents and Chemotherapy; 5-9 September 2014; Washington, DC.
12. Center for Drug Evaluation and Research (CDER). Application number: 206619Orig1s000 summary review for regulatory action. Rockville, MD: Food and Drug Administration, 2014. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/nda/2014/206619Orig1s000SumR.pdf. Accessed 27 January 2016.
13. Menon RM, Badri PS, Wang T, et al. Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir. J Hepatol 2015; 63:20-9.
14. Rodriguez-Torres M, Lawitz E, Cohen D, et al. Treatment-naïve, HCV genotype 1-infected subjects show significantly greater HCV RNA decreases when treated with 28 days of ABT-333 plus peginterferon and ribavirin compared to peginterferon and ribavirin alone. Hepatology 2009; 50:91A.
15. Gaultier IA, Cohen DE, Dumas EO, Larsen LM, Podsadecki TJ, Bernstein B. 12-Week efficacy and safety of ABT-072 or ABT-333 with pegylated interferon - + ribavirin, following 3-day monotherapy in genotype 1 HCV-infected treatment-naïve subjects. Presented at: 21st Conference of the Asian Pacific Association for the Study of the Liver; 17-20 February 2011; Bangkok, Thailand.
16. Sullivan GJ, Rodrigues-Torres M, Lawitz E, et al. ABT-267 combined with pegylated interferon alpha-2a/ribavirin in genotype 1 (GT1) HCV-infected treatment-naive subjects: 12 week antiviral and safety analysis. J Hepatology 2012; 56: S480.
17. Poordad F, Lawitz E, Kowdley KV, et al. Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med 2013; 368:45-53.
18. Epstein M, Felizarta F, Marbury T, et al. Study of ABT-267 2-day monotherapy followed by 12-week combination therapy in treatment-naive patients with chronic HCV genotype 1 infection. J Hepatol 2013; 58:S484.
19. Kowdley KV, Lawitz E, Poordad F, et al. Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med 2014; 370:222-32.
20. Sekar V, De Paepe E, Van Baelen B, et al. Pharmacokinetic/pharmacodynamic (PK/PD) analyses of darunavir in the TITAN study. Presented at: 11th Annual European AIDS Conference; 24-27 October 2014, 2007; Madrid, Spain.
21. Sekar V, Vanden Abeele C, Van Baelen B, et al. Pharmacokinetic-pharmacodynamic analyses of once-daily darunavir in the ARTEMIS study. Presented at: 15th Annual Conference on Retroviruses and Opportunistic Infection; 3-6 February 2008; Boston, Massachusetts.
22. Sekar V, De La Rosa G, Van de Casteele T, Spinosa-Guzman S, Vis P, Hoetelmans RMW. Pharmacokinetic (PK) and pharmacodynamic analyses of once- and twicedaily darunavir/ritonavir (DRV/r) in the ODIN trial [abstract]. J Int AIDS Soc 2010; 13:P185.
23. Molto J, Valle M, Ferrer E, et al. Reduced darunavir dose is as effective in maintaining HIV suppression as the standard dose in virologically suppressed HIV-infected patients. Presented at: 15th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy; 19 May 2014; Washington, DC.
24. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Drug interaction studies-study design, data analysis, implications for dosing, and labeling recommendations. Rockville, MD: Food and Drug Administration, 2012.
25. Badri PS, Dutta S, Wang H, et al. Drug interactions with the direct-acting antiviral combination of ombitasvir and paritaprevir/ritonavir (2D regimen). Antimicrob Agents Chemother 2015; 60:105-14.
26. Polepally A, Mensing S, Khatri A, et al. Dose- and formulation dependent nonlinear pharmacokinetic model of ABT-450, a protease inhibitor for the treatment of HCV: combined analyses from 12 phase 1 studies. J Pharmacokinet Pharmacodyn 2014; 41(suppl):S7-101.
27. Mensing S, Polepally A, Koenig D, et al. Population pharmacokinetics of paritaprevir, ombitasvir, dasabuvir, ritonavir, and ribavirin in patients with hepatitis C virus genotype 1 infection: combined analysis from 9 phase 1b/2 studies. AAPS J 2016; 18:270-80.
28. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Guidance for industry. Drug-induced liver injury: premarketing clinical evaluation. Rockville, MD: Food and Drug Administration, 2009.
29. Reyataz (atazanavir) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb, 2014.
30. Ruane P, Adeyemi O, Trinh R, et al. TURQUOISE-I study: use of ombitasvir/paritaprevir/ritonavir + dasabuvir + ribavirin in patients with HCV/HIV-1 coinfection on stable darunavir-containing antiretroviral therapy. Presented at: 15th European AIDS Conference; 21-24 October 2015; Barcelona, Spain.